Viroplazin Emergency Viral Outbreak Protocol

Purpose:
To provide veterinarians with clear, evidence-based guidance on the emergency application of **Viroplazin**, a broad-spectrum antiviral veterinary health product, during acute viral outbreaks in dogs, cats, and other susceptible species.

Scientific Rationale
Unlike antibiotics, where the dose is determined by achieving a tissue concentration sufficient to inhibit or kill bacteria, **Viroplazin functions as a substrate for the innate immune system**.

- Viroplazin enables the production of **hypothiocyanite ($OSCN^-$)**, a naturally occurring, non-toxic antiviral effector molecule.
- This reaction occurs **locally in inflamed tissue**.
- Therefore, **the required dosage correlates not with static body weight alone, but with the degree of systemic inflammation and viral activity**.

Key Principle:
The more inflamed tissue present, the more substrate is consumed, and the greater the supply required to achieve optimal antiviral activity.

Emergency Dosing Guidelines
Initial Phase (Day 1–2, Peak Infection):

- **Dosage:** *5 mg/kg body weight*, administered **3–4 times per day**.
- **Rationale:** At the onset of infection, viral replication and host inflammation are highest, requiring increased substrate availability to maximize hypothiocyanite production.

Stabilization Phase (Day 2–3 onward, as symptoms subside):

- **Dosage:** *5 mg/kg body weight*, administered **2–3 times per day**.
- **Rationale:** As inflammation decreases and viral burden drops, metabolic demand for substrate declines, allowing reduced dosing frequency while maintaining efficacy.

Administration Notes

- **Route of administration:** Viroplazin may be given orally, either directly or mixed with food, depending on the formulation.
- **Supportive care:** Ensure adequate hydration and provide general supportive therapy as indicated.
- **Monitoring**: Patient response should be evaluated closely during the first 24–48 hours. Early improvements—such as reduction in fever, lethargy, or respiratory distress—are strong indicators of substrate utilization and therapeutic effect.
- **Secondary bacterial infections:** If significant improvement is not observed with Viroplazin alone, it is highly suggestive that a concurrent bacterial infection is present. In such cases, appropriate antibiotic therapy should be initiated.

- **Clinical experience:** In cases where the condition is caused primarily by a viral infection, response to Viroplazin is typically rapid and marked, with noticeable clinical improvement within the first 1–2 days of treatment.
- In the case of vomiting and diarrhea the dosage may need adjustment as some part of the medicine may get expelled or lost.

Clinical Considerations

- **Species:** Dogs, cats, and pigs have demonstrated broad responsiveness to treatment.
- **Safety Profile:** Viroplazin has shown an **exceptional safety margin** in veterinary use, with no reported cases of systemic toxicity.
- **Treatment Window:** Early initiation of therapy at the first signs of viral outbreak yields the most favorable outcomes.
- **Combination Use:** Supportive therapies (fluids, anti-inflammatories, nutritional support) may be used alongside Viroplazin as indicated.

Summary Table: Emergency Protocol

Phase of Infection	**Dosage (mg/kg)**	**Frequency**	**Duration**	**Key Rationale**
Initial (Day 1–2)	5 mg/kg	3–4x daily	48 hrs	High inflammation = high substrate demand
Stabilization (Day 2-3 onward)	5 mg/kg	2–3x daily	Until resolution	Decreasing inflammation, sustained effect

Key Takeaway

Viroplazin's emergency dosing differs from conventional linear body-weight scaling. By aligning dosage frequency with **inflammatory status and viral burden**, veterinarians can maximize antiviral effectiveness while maintaining safety.